Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma

被引：0
|
作者：
Kröger, N
Shimoni, A
Zagrivnaja, M
Ayuk, F
Lioznov, M
Schieder, H
Renges, H
Fehse, B
Zabelina, T
Nagler, A
Zander, A
机构：
[1] Zander Univ, Hosp Hamburg, Hamburg, Germany
[2] Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel
来源：
BONE MARROW TRANSPLANTATION | 2005年 / 35卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
下载
收藏
页码：S47 / S47
页数：1
相关论文
共 50 条
  • [21] Cellular adoptive immunotherapy after allogeneic stem cell transplantation
    Schattenberg, AVMB
    Dolstra, H
    CURRENT OPINION IN ONCOLOGY, 2005, 17 (06) : 617 - 621
  • [22] Second allogeneic stem-cell transplantation or donor lymphocyte infusion in patients who relapse after transplantation?
    Robin, Marie
    LANCET HAEMATOLOGY, 2024, 11 (09): : e642 - e643
  • [23] Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma
    Bellucci, R
    Alyea, EP
    Weller, E
    Chillemi, A
    Hochberg, E
    Wu, CJ
    Canning, C
    Schlossman, R
    Soiffer, RJ
    Anderson, KC
    Ritz, J
    BLOOD, 2002, 99 (12) : 4610 - 4617
  • [24] Thalidomide as salvage therapy for relapsed multiple myeloma after allogeneic stem cell transplantation
    Yakoub-Agha, I
    Mohty, M
    Attal, M
    Marit, G
    Bulabois, C
    Sotto, JJ
    Gratecos, N
    Rio, B
    Vernant, JP
    Facon, T
    Jouet, JP
    BONE MARROW TRANSPLANTATION, 2004, 33 : S156 - S156
  • [25] ADOPTIVE THERAPY WITH DONOR LYMPHOCYTE INFUSION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION - EXPERIENCE OF THE POLISH PEDIATRIC GROUP FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION (PPGHSCT)
    Gozdzik, J.
    Rewucka-siewiera, K.
    Krasowska-Kwiecien, A.
    Pieczonka, A.
    Debski, R.
    Zaucha-Prazmo, A.
    Drabko, K.
    Kowalczyk, J.
    Wysocki, M.
    Gorczynska, E.
    Kalwak, K.
    Chybicka, A.
    Wachowiak, J.
    BONE MARROW TRANSPLANTATION, 2014, 49 : S159 - S160
  • [26] DONOR LYMPHOCYTE INFUSION FOR AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS OF 57 PATIENTS.
    Sperotto, A.
    Damiani, D.
    Michelutti, A.
    Patriarca, F.
    Cavallin, M.
    Battista, M.
    Zanini, F.
    Geromin, A.
    Cerno, M.
    Fanin, R.
    BONE MARROW TRANSPLANTATION, 2014, 49 : S135 - S135
  • [27] Efficacy of donor lymphocyte infusion in patients after different types of allogeneic hematopoietic stem cell transplantation
    Slesarchuk, O. A.
    Babenko, E. V.
    Semenova, E. V.
    Bondarenko, S. N.
    Estrina, M. A.
    Morozova, E. V.
    Paina, O. V.
    Vavilov, V. N.
    Smirnov, B. I.
    Zubarovskaya, L. S.
    Afanasyev, B. V.
    TERAPEVTICHESKII ARKHIV, 2013, 85 (07): : 26 - 33
  • [28] JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation
    Kroeger, Nicolaus
    Alchalby, Haefaa
    Klyuchnikov, Evgeny
    Badbaran, Anita
    Hildebrandt, York
    Ayuk, Francis
    Bacher, Ulrike
    Bock, Oliver
    Kvasnicka, Michael
    Fehse, Boris
    Zander, Axel
    BLOOD, 2009, 113 (08) : 1866 - 1868
  • [29] Donor lymphocyte infusion for the treatment of relapse after allogeneic hematopoietic stem cell transplantation
    Helg, C
    Starobinski, M
    Jeannet, M
    Chapuis, B
    LEUKEMIA & LYMPHOMA, 1998, 29 (3-4) : 301 - 313
  • [30] Timing of donor lymphocyte apheresis for immunotherapy after allogeneic blood stem cell transplantation
    Nowak-Hamau, S
    Krug, E
    Maccari, B
    Schmitt, A
    Reinhardt, P
    Kubanek, B
    Wiesneth, M
    BONE MARROW TRANSPLANTATION, 2002, 29 : S112 - S112
12345